A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Brand Name :
Lorflex Plus, Flexilor-P, Mitilor, Lornoxi-P, Lonax, Lorsaid, Flexilor, Lornigesic, Noxi, Lirnor, Lorwalk, Camri, Mitilor, Flexilor, Neucam, Zelorn, Lornistar-P
Synonyms :
lornoxicam
Class :
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Dosage Forms & Strengths
Tablet
4 mg
8 mg
Take a dose of 8 to 16 mg orally daily
Daily dose not more than 24 mg
Take a dose of 12 mg daily in 2 to 3 divided doses
Daily dose not more than 16 mg
Not determined
Refer to adult dosing
NSAIDs may increase the serum concentration of Lithium
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
CYP2C9 enhancers may decrease the the bioavailability of lornoxicam
Ketorolac may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
When loracarbef is used together with lornoxicam, the risk or seriousness of nephrotoxicity is enhanced
When lornoxicam is used together with sertraline, the risk or seriousness of bleeding may be enhanced
When lornoxicam is used together with bufexamac, this leads to enhanced risk or seriousness of adverse outcomes
lornoxicam leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
lornoxicam: it may decrease the excretion rate of abacavir
When lornoxicam is used together with nifenazone, this leads to enhanced risk or seriousness of adverse events
it enhances the serum potassium levels
may enhance the serum concentration of CYP2C9 inhibitors
may increase the anticoagulation effect when combined
abatacept: it may increase the metabolism of lornoxicam
abrocitinib: it may decrease the metabolism of lornoxicam
acebutolol: it may decrease the metabolism of lornoxicam
Actions and Spectrum
lornoxicam works by inhibiting the enzyme cyclooxygenase (COX), specifically the isoform COX-1 and COX-2.
By inhibiting COX, it reduces the production of prostaglandins, which in turn helps to alleviate pain, reduce inflammation, and lower fever.
Frequency not defined
Dyspepsia
Nausea
Abdominal pain
Diarrhea
Hematologic disorders
CNS effects
Vomiting
Headache
Visual disturbance
Dizziness
Fluid retention
Photosensitivity
Palpitation
Insomnia
Tinnitus
Nephrotoxicity
Alveolitis
Colitis induction
Stomatitis
Pancreatitis
Toxic epidermal necrolysis
Somnolence
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy consideration:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
<b>Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
COX-1 is involved in maintaining physiological functions like gastrointestinal protection and platelet aggregation, while COX-2 is associated with inflammation.
Preferential inhibition of COX-2 helps to reduce inflammation and pain while potentially minimizing some of the gastrointestinal side effects associated with COX-1 inhibition.
Pharmacodynamics
By inhibiting the production of prostaglandins, lornoxicam influences physiological processes which involve prostaglandins sensitize pain receptors at the site of injury or inflammation, contributing to the perception of pain.
By reducing prostaglandin production, lornoxicam helps alleviate pain associated with various conditions.
Pharmacokinetics
Absorption
lornoxicam is absorbed from the gastrointestinal tract.
Distribution
lornoxicam is distributed throughout the body’s tissues.
Metabolism
lornoxicam undergoes metabolism in the liver.
Elimination and excretion
lornoxicam is eliminated from the body through the kidneys.
Administration
lornoxicam is available in the form of oral tablets or capsules.
Patient information leaflet
Generic Name: lornoxicam
Why do we use lornoxicam?
lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that is used to relieve pain and reduce inflammation.
lornoxicam is indicated to manage the pain and inflammation associated with osteoarthritis.
lornoxicam can be used to alleviate pain and reduce inflammation in patients with rheumatoid arthritis.